FNAM (Evolutionary Genomics) 3-Year Revenue Growth Rate: 0.00% (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics 3-Year Revenue Growth Rate?

Evolutionary Genomics FNAM 31 3-Year Revenue Growth Rate is 0.00% as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Evolutionary Genomics's Revenue per Share for the three months ended in Dec. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Evolutionary Genomics  (OTCPK:FNAM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Evolutionary Genomics 3-Year Revenue Growth Rate Related Terms

FNAM vs BXRX, GNCA, XSNX: 3-Year Revenue Growth Rate Comparison

For the Biotechnology subindustry, Evolutionary Genomics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics 3-Year Revenue Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's 3-Year Revenue Growth Rate falls into.


FNAM
31GF Score
Evolutionary Genomics Inc FNAM
3-Year Revenue Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

What does a 3-Year Revenue Growth Rate of 0.00% mean?
Evolutionary Genomics (FNAM) has a 3-Year Revenue Growth Rate of 0.00% as of Dec. 2022. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' 3-Year Revenue Growth Rate too high?
Evolutionary Genomics' current 3-Year Revenue Growth Rate is 0.00%. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' 3-Year Revenue Growth Rate compare to BXRX and GNCA?
Evolutionary Genomics' 3-Year Revenue Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. The industry median 3-Year Revenue Growth Rate is 3.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.30, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Evolutionary Genomics and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolutionary Genomics's current 3-Year Revenue Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current 3-Year Revenue Growth Rate of 0.00%. The current 3-Year Revenue Growth Rate is 0.00%. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current 3-Year Revenue Growth Rate is 0.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price